KOSDAQBiotech & Pharma067080

Dae Hwa Pharm

₩8,920 0.00%2026-11-18 close
Market Cap
₩166.1B
Turnover
₩300M
Volume
30K
Shares out.
18.6M
PER
69.8×
PBR
2.3×
EPS
₩136
Dividend Yield
1.58%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩150 per share · Prices as of the 2026-11-18 close

01

Report overview

DAE HWA Pharm: China Sales Growth Amid Earnings Swings

China supply sales of oral anticancer drug Liporaxel drove a first-half 2026 rebound, but the Q3 2026 operating loss leaves earnings durability unconfirmed.

  1. 1

    Revenue for 2025 was KRW 143.1 billion, down 4.2% year on year, and operating profit fell 52.9% to KRW 3.16 billion.

  2. 2

    According to press reports, China-region sales in the first half of 2026 reached KRW 10.0 billion, 5.65 times the prior-year period.

  3. 3

    In Q3 2026, operating loss widened to KRW 1.29 billion and net loss attributable to controlling shareholders reached KRW 2.5 billion.

  4. 4

    In October 2026, supply contracts for the Middle East and North Africa and for Malaysia and Brunei ended without revenue, and the exchange issued a notice of possible unfaithful-disclosure designation over delayed disclosure.

  5. 5

    In April 2026, the company disclosed a corporate value-up plan that reaffirmed annual dividends and a stable dividend policy.

02

Business structure

DAE HWA Pharm is a mid-sized pharmaceutical company that centers on drug manufacturing and sales and also runs pharmaceutical wholesale, API, cosmetics and medical devices, and medical information systems.

According to the company profile, it produces solid dosage forms, transdermal patches and anticancer drugs at a GMP-certified third plant.

Based on segment figures in the 2026 first-quarter report, the drug manufacturing and sales segment generated KRW 105.3 billion in 2025 before intragroup eliminations, the largest share, followed by pharmaceutical wholesale at KRW 24.3 billion, APIs at KRW 17.8 billion, and cosmetics and medical devices at KRW 7.9 billion.

Within manufacturing, Cefamethyl tablets contributed KRW 8.0 billion, Magnesium tablets KRW 6.5 billion, Phlosupan tablets KRW 4.5 billion, OEM patch products KRW 23.8 billion, and other products such as Daehwa Ibuprofen KRW 55.6 billion, of which KRW 9.9 billion was exports.

The API segment's revenue fell to KRW 1.7 billion in the first quarter of 2026, a steep drop from KRW 17.8 billion for full-year 2025. Cosmetics and medical devices revenue also declined to KRW 2.1 billion in the same quarter.

Overseas, the oral anticancer drug Liporaxel is the core product, generating supply revenue in China after gastric cancer approval and reimbursement listing. The quarterly report says the company is expanding medical aesthetic devices and pursuing technology transfers and a joint venture for localization abroad.

In dementia treatment, oral donepezil tablets are the cited competing product, and the company describes a donepezil patch built on its DH-TDDS platform as having completed nonclinical work. The same report puts the domestic market size for this therapeutic area at KRW 150 billion.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩36.7B₩1B2.9%
2025Q4₩33.7B₩700M2.1%
2026Q1₩37B₩500M1.2%
2026Q2₩41.3B₩3.3B8.1%
2026Q3₩35.3B-₩1.3B−3.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩131.9B₩5.8B₩1.1B4.4%1.4%143.7%
2023₩141.4B₩2B-₩1.1B1.4%−1.6%183.3%
2024₩149.4B₩6.7B₩500M4.5%0.7%169.6%
2025₩143.1B₩3.2B₩1.7B2.2%2.2%166.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a DART-disclosed basis, revenue rose from KRW 131.9 billion in 2022 to KRW 141.4 billion in 2023 (up 7.2% year on year) and KRW 149.4 billion in 2024 (up 5.7%), then fell to KRW 143.1 billion in 2025 (down 4.2%). Among the years from 2022 to 2025, 2024 was the largest year for revenue.

Operating profit went from KRW 5.85 billion in 2022 to KRW 1.96 billion in 2023 (down 66.4%), recovered to KRW 6.71 billion in 2024 (up 241.8%), and then fell to KRW 3.16 billion in 2025 (down 52.9%).

The operating margin was 4.4% in 2022, 1.4% in 2023, 4.5% in 2024 and 2.2% in 2025, so the 2025 decline came with both lower sales and a thinner margin.

Net income attributable to controlling shareholders swung to a loss of KRW 1.15 billion in 2023 from a profit in 2022, returned to a profit of KRW 531 million in 2024, and reached KRW 1.65 billion in 2025 (up 211.2%).

Net income including non-controlling interests is a different figure and stood at KRW 2.33 billion in 2025. At the end of 2025, total equity was KRW 79.1 billion, of which KRW 74.1 billion belonged to controlling shareholders, and total liabilities were KRW 131.7 billion.

The debt ratio rose from 143.7% in 2022 to 183.3% in 2023, then eased to 169.6% in 2024 and 166.4% in 2025. Operating cash flow was KRW 8.19 billion in 2022, negative at -KRW 214 million in 2023, and then KRW 5.25 billion in 2024 and KRW 5.43 billion in 2025.

On a quarterly basis, revenue fell from KRW 36.7 billion in Q3 2025 to KRW 33.7 billion in Q4 2025 (down 8.3% quarter on quarter), then rose to KRW 37 billion in Q1 2026 and KRW 41.3 billion in Q2 2026 (up 11.5%).

Operating profit stayed low at KRW 1.05 billion, KRW 699 million and KRW 454 million across Q3 2025, Q4 2025 and Q1 2026, then jumped to KRW 3.33 billion in Q2 2026 (up 633.9%).

In Q3 2026, revenue was KRW 35.3 billion (down 14.5% quarter on quarter and down 3.9% year on year), and the company posted an operating loss of KRW 1.29 billion. Net income attributable to controlling shareholders alternated between profit and loss across the last five quarters.

The trailing four-quarter total from Q4 2025 through Q3 2026 was KRW 2.36 billion.

According to press coverage of the third quarter, gross profit fell from KRW 12.2 billion to KRW 10.6 billion while selling and administrative expenses rose from KRW 11.2 billion to KRW 11.9 billion, and weakness in the API and cosmetics and medical device segments offset gains in drug manufacturing.

Q4 2025 net income attributable to controlling shareholders (KRW 3.18 billion) was far above operating profit (KRW 699 million), which suggests non-operating items affected the quarterly net result.

05

Industry analysis

Daehwa's earnings swings depend heavily on the nature of its overseas business. In China, the company built a path for its oral anticancer drug Liporaxel that runs from approval through reimbursement listing, supply and revenue.

By contrast, contracts in the Middle East and North Africa and in Malaysia and Brunei ended without supply, either because local approval was not completed or because the partner could not continue.

This shows that for Korean drugmakers relying on partner-led export deals, local registration and partner succession risks translate directly into reported results. In domestic dementia treatment, the quarterly report puts the market at KRW 150 billion, and oral donepezil tablets are the cited competing product.

A patch format can offer adherence advantages, but the company itself describes its donepezil patch as at an early development stage, with timing hard to predict. Among listed peers in the sector, Hanmi Pharm and Yuhan are considerably larger in scale, so Daehwa is relatively small by comparison.

Expansion abroad and the planned joint venture will depend on how well the company works with local partners. If competing paclitaxel-based drugs gain share in China, prescription share changes could affect future revenue.

06

Outlook

The most concrete driver is the China supply contract for Liporaxel. In December 2025, the company signed a KRW 45.1 billion supply contract with RMX Biopharma that runs from 2026 through the end of 2027.

In the first half of 2026 alone, this contract generated KRW 96.9 million in supply revenue, equal to 21.4% of the total contract value. Because China-region sales in the first half exceeded the total revenue increase, the pace of this contract will be a key variable for results after Q4 2026.

Whether the additional breast cancer indication leads to wider prescribing and follow-on supply remains to be seen in future reports. On the other side, two long-term overseas contracts ended without supply, which raises questions about the predictability of the overseas pipeline.

The exchange's notice of possible unfaithful-disclosure designation also points to the need for better disclosure timing. In its 2026 corporate value-up plan, the company reaffirmed annual dividends and a stable dividend policy.

It is also pursuing expansion in medical aesthetic devices and a joint venture for localization abroad. The donepezil patch has completed nonclinical work, but the company describes the timing of clinical entry as difficult to predict.

07

Valuation

PER
69.8×
PBR
2.3×
ROE
3.2%
EPS
₩136
BPS
₩4,191
Dividend per share
₩150

Valuation should be read against a small earnings base. Net income attributable to controlling shareholders totaled only KRW 2.36 billion over the last four quarters, so earnings-based multiples move sharply with a single quarter's result, as the Q3 2026 swing into a loss illustrates.

On an asset basis, market capitalization is more than twice the KRW 74.1 billion of equity attributable to controlling shareholders, which places the stock in a range of substantial premium to book value. Some observers read this premium as reflecting growth expectations tied to China sales of Liporaxel.

The company has disclosed annual dividends and a stable dividend policy, but dividend yield moves with the share price, so dividend continuity should be assessed together with the earnings trend.

The debt ratio of 166.4% is relatively high, while operating cash flow has stayed positive since 2024, and both points enter any multiple-based reading. Because the operating margin has moved within a range of 1.4% to 4.5% since 2022, the margin assumption behind any valuation has not yet settled into a stable range.

Over several years, controlling-shareholder net income moved from a loss in 2023 back to profit, and the first half of 2026 showed an earnings recovery.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

China supply revenue is materializing

Press reports said China-region sales in the first half of 2026 reached KRW 10.0 billion, 5.65 times the prior-year level. Liporaxel moved from approval and reimbursement listing to supply revenue, and it has added a breast cancer indication. Revenue from the KRW 45.1 billion contract signed in December 2025 also appeared in the first half.

Earnings recovery trend

Press reports put consolidated operating profit for the first half of 2026 at KRW 3.78 billion, up 167% from the prior-year period, and net income turned to a profit from a loss. Net income attributable to controlling shareholders rose to KRW 1.65 billion in 2025 after returning to profit in 2024.

Written shareholder return policy

In its 2026 corporate value-up plan, the company disclosed that it has paid dividends every year and intends to keep a stable dividend policy. It said dividend decisions will weigh growth against shareholder returns. Total equity stood at KRW 79.1 billion at the end of 2025.

09

Bear factors

Q3 loss and rising costs

Operating loss in Q3 2026 was KRW 1.29 billion, a swing into loss, and net loss attributable to controlling shareholders widened to KRW 2.5 billion. Press coverage said gross profit fell while selling and administrative expenses rose, hurting profitability. Weakness in the API and cosmetics and medical device segments offset gains in drug manufacturing.

Overseas contract exits and disclosure risk

A KRW 11.9 billion supply contract for the Middle East and North Africa ended without any revenue, and a KRW 9.66 billion contract for Malaysia and Brunei was terminated by mutual agreement with no supply.

The exchange classified the contract cancellation as a disclosure reversal and the late notice of the cancellation trigger as a disclosure failure, leading to the notice of possible designation.

Balance sheet and cash flow volatility

Total liabilities stood at KRW 131.7 billion at the end of 2025, above total equity of KRW 79.1 billion, which gives a debt ratio of 166.4%. Operating cash flow was negative in 2023 at -KRW 214 million, so the stability of cash generation since 2024 is still being tested. The operating margin declined to 2.2% in 2025.

10

Risk factors

Dependence on China and approval/reimbursement

The center of overseas revenue has shifted to China supply of Liporaxel. Growth there depends on prescribing expansion after approval and reimbursement, and whether the breast cancer indication leads to actual prescriptions remains unconfirmed. Growing competition from other drugs in China could change prescription share.

Contract and disclosure management risk

Two overseas supply contracts ended without supply, and outside events such as partner acquisition and business suspension fed directly into results. The exchange raised delayed disclosure as an issue and issued a notice of possible designation. Late disclosure can weaken confidence in the information used for decisions.

Profitability swings and API weakness

Operating profit swung from KRW 5.85 billion in 2022 to KRW 6.71 billion in 2024 and KRW 3.16 billion in 2025. API segment revenue fell to KRW 1.7 billion in the first quarter of 2026, and press reports said cumulative API revenue for the first nine months of 2026 declined 44.0% year on year. Sustaining profit without an API recovery may be difficult.

11

What to watch next

  1. Late December 2026

    This marks the close of Q4 2026. The checkpoints are whether operating profit recovers after the Q3 loss and whether China supply revenue for Liporaxel holds at the quarterly level.

  2. Around February 2027

    This is the usual timing for the preliminary annual 2026 results. It will show the full-year 2026 operating margin and the direction of net income attributable to controlling shareholders.

  3. End of March 2027

    This is the filing deadline for the 2026 annual report, and the period when dividends are approved at the annual shareholder meeting. Watch the dividend level, changes in the debt ratio, and how the overseas contract exits are reflected in results.

  4. Mid-May 2027

    This is when the Q1 2027 quarterly report is due. Check whether API segment revenue recovers and how quarterly China supply revenue trends.

  5. End of 2027

    This is when the Liporaxel supply contract with RMX Biopharma expires. Watch whether follow-on contracts are signed and how supply volumes change as the breast cancer indication expands.

12

Overall view

DAE HWA Pharm is a company where China supply revenue for Liporaxel has started to flow through to reported profit. In the first half of 2026, consolidated revenue reached KRW 78.3 billion and operating profit KRW 3.78 billion, so both sales and profit improved.

However, the Q3 2026 operating loss of KRW 1.29 billion and net loss attributable to controlling shareholders of KRW 2.5 billion mean that earnings durability is still being tested.

Two overseas supply contracts ended without supply, and the exchange's notice of possible unfaithful-disclosure designation leaves questions about the predictability of the overseas business and disclosure practice.

On the financial side, the 166.4% debt ratio, with total liabilities above total equity of KRW 79.1 billion, is a burden factor, while operating cash flow has stayed positive since 2024. The company has disclosed annual dividends and a stable dividend policy.

The next checkpoints are the Q4 2026 results and the 2026 annual report, and whether follow-on contracts are signed after the Liporaxel supply contract ends in late 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. jobkorea.co.kr
  2. comp.wisereport.co.kr
  3. dailypharm.com
  4. kind.krx.co.kr
  5. biz.newdaily.co.kr
  6. eduinfom.com
  7. saramin.co.kr
  8. m.news.nate.com
  9. whynotsellreport.com
  10. littlebproject.com
  11. 101.brokdam.com
  12. judal.co.kr
  13. judal.co.kr
  14. judal.co.kr
  15. judal.co.kr

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis